Clinical trial of BNC 210 in patients with anxiety disorders in the USA

Trial Profile

Clinical trial of BNC 210 in patients with anxiety disorders in the USA

Recruiting
Phase of Trial: Phase I

Latest Information Update: 21 Dec 2012

At a glance

  • Drugs BNC 210 (Primary)
  • Indications Anxiety disorders
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 21 Dec 2012 Status changed from planning to recruiting based on information reported in a Bionomics media release.
    • 28 Nov 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top